



## PRESS RELEASE

### Aenova expands production capacities at the Tittmoning site

- **On the company site of Dragenopharm Apotheker Püschl GmbH, member of the Aenova Group, a new production building is under construction.**
- **The production capacity of the site can thus be increased to over 10 billion tablets per year.**
- **The investment of about € 25 million lays the cornerstone for more than 100 new jobs and is part of further investment projects of the Aenova Group.**

Tittmoning, 13 October 2020 - Dragenopharm Apotheker Püschl GmbH is a renowned manufacturer of pharmaceuticals and dietary supplements based in Tittmoning, Upper Bavaria. The products manufactured there are not sold under the own name, but are exclusively produced in customer order for the international pharmaceutical and health industry. Since 2008 the company belongs to the Aenova Group. In order to meet the constantly growing demand for pharmaceuticals "Made in Tittmoning", the Aenova Group decided at the beginning of the year to expand the production capacities in Tittmoning. For this purpose, a new, more than 3,100 sqm large production building is being constructed on the company's premises in cooperation with the site owner, Mrs. Marianne Greither, since April 2020. The operations are to start already in mid 2021. The investment volume for the first of three planned expansion stages amounts to about € 25 million and is one of the strategic growth projects of the Aenova Group. When the last expansion stage is reached, more than 100 new state-of-the-art jobs will be created.

Not least because of the COVID19 pandemic, the production of drugs at European sites with a maximum of quality and delivery reliability is moving into the public interest.


"Pharmaceutical contract manufacturing plays a decisive role in supplying the population with



drugs and food supplements. One of these 'silent players' behind the big, well-known pharmaceutical companies is the Aenova Group", explains Jan Kengelbach, CEO of the Aenova Group. With over 4,300 employees, the company manufactures at 15 locations for almost all renowned pharmaceutical companies worldwide. "In Tittmoning, our largest site, we are again investing in ultra-modern production capacities after several successful expansion projects. This is part of our growth strategy, which is being continued at other locations", Jan Kengelbach continues.

Tablets and capsules are the most commonly used forms of medication on the German and international markets. "Within the Aenova Group, the Tittmoning site is the competence center for these dosage forms. After the expansion we will be able to serve the market demand even better", adds Christine Beck, Head of the Solid Dosage Form Division at the Aenova Group. The company manufactures other dosage forms such as injectables, soft gelatine capsules, ointments, creams and liquids at other locations in its international production network.

With around 630 employees, the Tittmoning site produced 7.5 billion tablets for more than 100 customers on all continents last year, making it one of the largest internationally active contract manufacturers for tablets even before the expansion. "The expansion project is a confirmation of the successful work of the past years. With a future annual capacity of over 10 billion tablets, the site will not only reach a new order of magnitude, but will also face additional challenges," explains Dr. Helmut Stibich, Site Manager. At full capacity, the expansion will create over 100 more qualified and future-oriented jobs at the Tittmoning site. Only a part of these will be covered by the established training and further education program, which guarantees a permanent employment relationship for every graduate. Dragenopharm Apotheker Püschl GmbH is already today the biggest employer at the location.



[Caption:]

The Aenova Group produces around 7.5 billion tablets at the Tittmoning site. Tablets are a key dosage form for drugs on the market.



[Caption:]

The Dragenopharm Apotheke Püschl GmbH, member of the Aenova Group, is the biggest employer in Tittmoning.



[Caption:]

At Aenova's site in Tittmoning, production capacities will be increased by about one third. The new production building is scheduled to go into operation in mid 2021.

**Aenova Group**

*The Aenova Group is one of the leading contract manufacturing companies in the pharmaceutical and healthcare industry. With high quality standards, innovative technologies*



*and reliable delivery reliability, Aenova as CDMO has become the European market leader for the development and production of all common dosage forms and product groups in the business-to-business sector. The company, headquartered near Munich, operates 15 production facilities and several sales offices in ten countries around the world. More than 4,300 employees contribute to the group's success.*

**Contact for further inquiries:**

Dr. Susanne Knabe  
Head of Communications & PR  
Aenova Holding GmbH  
Berger Strasse 8-10  
D-82319 Starnberg

Mobile: +49 170 22 368 42  
e-mail: [susanne.knabe@aenova-group.com](mailto:susanne.knabe@aenova-group.com)